Were on the cusp of providing individual proof-of-idea data for our antibiotic.

We are self-confident that the Phase 2 trial will confirm AFN-1252 as a potent and well tolerated anti-Staph antibiotic commented Dr. Hafkin, Chief Medical Officer of Affinium Pharmaceuticals. Related StoriesTackling MRSA with bacteriophageVirginia Tech scientists discover new remedies to focus on antibiotic-resistant bacteriaShared decision making between doctors and individuals useful in fight antibiotic resistanceAccording to Leisa Dennehy, Commercial & Corporate Development Advisor at Affinium, general market trends with physicians obviously indicates the need for an IV and oral antibiotic with a better safety profile in comparison to vancomycin or linezolid, without compromising potency against MRSA.The framework is defined by international initiatives by industries and governments: for example more than 500 investors request global listed companies to survey their CO2 relevant business data through the Carbon Disclosure Project from the UK. Global initiatives for Green Chemistry such as the conventions from Stockholm, Basel and Rotterdam, the OECD and the regulatory authorities of developed countries will work to create global specifications for sustainable risk and chemical substances management.